The Joint Project Manager for Medical Countermeasure Systems (JPM MCS), a component of the Joint Program Executive Office for Chemical and Biological Defense, develops and acquires innovative medical solutions and systems to combat chemical, biological, radiological, and nuclear (CBRN) threats and emerging infectious diseases.
JPM-MCS specializes in advanced development of drugs, biologics, and devices that have reached the Phase 1 clinical trials or that already have a Food and Drug Administration Investigational New Drug application on file.
JPM-MCS was formed in 2013 through the consolidation of three former medical joint project management offices: Chemical Biological Medical Systems (CBMS), Transformational Medical Technologies (TMT), and Medical Countermeasures Advanced Development and Manufacturing (MCM ADM).
Product management and support offices under JPM-MCS include:
Editor’s Picks: Articles and resources related to JPM-MCS. Links may lead to external sites.